Literature DB >> 8397270

Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia.

T van der Poll1, J Jansen, D van Leenen, M von der Möhlen, M Levi, H ten Cate, H Gallati, J W ten Cate, S J van Deventer.   

Abstract

To assess the role of tumor necrosis factor (TNF) in the appearance of soluble TNF receptors (sTNFRs), 20 consecutive patients with a clinical diagnosis of sepsis were studied as were 7 chimpanzees after administration of endotoxin (4 ng/kg) with or without pentoxifylline. The patients had markedly elevated serum levels of sTNFR-p55 and sTNFR-p75 compared with healthy controls (P < .0001 for both receptors). The levels of both soluble receptors correlated with simultaneously measured immunoreactive TNF concentrations (p55: r = .63, P < .01; p75: r = .69, P < .001). In the chimpanzees, endotoxin induced subsequent rises in the serum concentrations of TNF and sTNFRs. Although pentoxifylline reduced the TNF response to intravenous endotoxin to 20% (P < .05), the appearance of sTNFRs was only moderately inhibited (sTNFR-p55 to 79% on average, P < .05; sTNFR-p75 to 77%, P = .12). These results indicate that TNF either does not play an important role in the appearance of sTNFRs in systemic infection or that a small amount of TNF remaining in the circulation after some bacterial challenges is sufficient to preserve the secretion of its soluble receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397270     DOI: 10.1093/infdis/168.4.955

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Time course of cytokine levels in sepsis.

Authors:  L G Thijs; C E Hack
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440

2.  Increased serum levels of soluble tumor necrosis factor receptors (sTNF-Rs) in children and adolescents with vertically and horizontally transmitted HIV infection.

Authors:  M Weiss; M Martignoni; T Petropoulou; B Sölder; B H Belohradsky
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

3.  Tumor necrosis factor alpha (TNF-alpha) and sepsis: evidence for a role in host defense.

Authors:  O Rigato; S Ujvari; A Castelo; R Salomão
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

4.  Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody.

Authors:  J Jansen; T van der Poll; M Levi; H ten Cate; H Gallati; J W ten Cate; S J van Deventer
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

5.  Soluble tumor necrosis factor receptors in febrile neutropenic cancer patients.

Authors:  W V Kern; A Engel; P Kern
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553

6.  Soluble tumour necrosis factor (TNF)-receptor levels in serum as markers of anti-viral host reactivity.

Authors:  C Bartholdy; A Nansen; O Marker; A R Thomsen
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

7.  Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations.

Authors:  M A Dentener; E C Creutzberg; A M Schols; A Mantovani; C van't Veer; W A Buurman; E F Wouters
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

8.  Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees.

Authors:  T van der Poll; M Levi; H ten Cate; J Jansen; B J Biemond; B L Haagmans; A Eerenberg; S J van Deventer; C E Hack; J W ten Cate
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

9.  Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.

Authors:  J M Tramontana; U Utaipat; A Molloy; P Akarasewi; M Burroughs; S Makonkawkeyoon; B Johnson; J D Klausner; W Rom; G Kaplan
Journal:  Mol Med       Date:  1995-05       Impact factor: 6.354

10.  Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI.

Authors:  M A Rogy; L L Moldawer; H S Oldenburg; W A Thompson; W J Montegut; S A Stackpole; A Kumar; M A Palladino; M N Marra; S F Lowry
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.